The analysis of treatment-related leukemia after taxan and platinum based chemotherapy, retrospective multicenter study.
Not Applicable
Recruiting
- Conditions
- Gynecologic malignancies
- Registration Number
- JPRN-UMIN000018329
- Lead Sponsor
- Gynecologic Oncology Trial and Investigation Consortium of North Kanto (GOTIC)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 5000
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with radiation therapy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of treatment-related leukemia after only taxan and platinum(Pt) based chemotherapy.
- Secondary Outcome Measures
Name Time Method Incidence of TRL according to the combination of Taxan and Pt. Relationship of total dose of Taxan and the Pt and the incidence of TRL. Duration from the last chemotherapy to the TRL. Characteristics of chromosomal abnormality and karyo -type of TRL. Treatment and outcome of TRL.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link taxane and platinum chemotherapy to treatment-related leukemia in gynecologic malignancies?
How does taxane-platinum regimen compare to other chemotherapies in causing secondary leukemias in ovarian or cervical cancer patients?
Which biomarkers (e.g., TP53, BRCA) predict risk of treatment-related leukemia after taxane and platinum-based therapy in gynecologic cancers?
What are the long-term adverse event profiles of taxane-platinum regimens in JPRN-UMIN000018329, including myelosuppression and leukemic transformation?
Are there combination strategies with PARP inhibitors or immunotherapy that reduce leukemia risk while maintaining efficacy in taxane-platinum-treated gynecologic malignancies?